Key result
Ramipril extends lifespan ~111% in a murine model of progressive renal fibrosis, outperforming candesartan.
Why the study?
Prospective trials with clinical end points comparing antifibrotic effects of ACE inhibitors and AT1 antagonists do not exist.
Does ramipril or candesartan improve lifespan and reduce renal fibrosis in COL4A3-/- mice?
Does ramipril or candesartan improve lifespan and reduce renal fibrosis in COL4A3-/- mice?
In a murine model of progressive renal fibrosis, the ACE inhibitor ramipril demonstrated a greater antifibrotic and nephroprotective effect, including a larger increase in lifespan, compared to the AT1 antagonist candesartan.
Answers are grounded in this paper and cite their sources.
Supports ACEi over ARB in experimental renal fibrosis; leaves open human translation and practice change.
BACKGROUND: Several studies have shown antifibrotic effects of angiotensin converting enzyme (ACE) inhibitors as well as of angiotensin receptor 1 (AT1) antagonists, however, prospective trials with clinical end points comparing these effects do not exist. COL4A3-/- mice develop a non-hypertensive progressive renal fibrosis. We used this animal model to compare the potential of ACE inhibitor vs AT1 antagonist to prevent renal fibrosis irrespective of blood pressure-dependent involvement by the renin system. METHODS: COL4A3-/- mice were treated with placebo, ramipril or candesartan. Blood pressure, proteinuria, serum urea and lifespan were monitored. Renal matrix was characterized by immuno-histochemistry, light and electron microscopy. Further biochemical analysis was provided using cDNA microarray and western blot techniques. RESULTS: Untreated mice died of renal failure after 71+/-6 days. Ramipril and candesartan both delayed onset and reduced the extent of proteinuria. Both had minor effects on blood pressure and postponed onset of uraemia. Ramipril increased lifespan by 111% to 150+/-21 days (P<0.01), whereas candesartan resulted in only a 38% prolongation to 98+/-16 days (P<0.01). Ramipril reduced glomerular and tubulo-interstitial fibrosis and numbers of activated fibroblasts to a greater extent than candesartan. Microarray and western blot analysis revealed a higher antifibrotic potential of ramipril in terms of downregulation of TGFbeta, connective tissue growth factor, metalloproteinases and extracellular matrix proteins. CONCLUSIONS: The results indicate an antifibrotic, nephroprotective effect of ACE inhibitors and AT1 antagonists in an animal model of progressive renal fibrosis. The greater antifibrotic effect of ramipril at the maximal therapeutic doses employed may not be explained by different antiproteinuric or blood pressure lowering properties, but by-in contrast to candesartan-its ability to hinder the proinflammatory, profibrotic activation of the angiotensin receptor 2.
No takes yet. Share an insight, caveat, or question.
Schulze-Lohoff et al. (2004) studied Progressive renal fibrosis. Ramipril and Candesartan vs. Placebo (untreated) was evaluated on Lifespan (111% increase, p=<0.01). In a murine model of progressive renal fibrosis, ramipril increased lifespan by 111% compared to a 38% increase with candesartan versus untreated controls.
Synapse has enriched 10 related papers. Consider them for comparative context: